Incorporation & Overview
Founded in January 1999, Sai Life Sciences Limited is a prominent player in the research, development, and production of small-molecule new chemical entities. The company delivers tailored solutions to leading biotech and pharmaceutical innovators worldwide.
Business Overview
Client Base:
- During FY 2024 and up to September 30, 2024, the company catered to a diverse portfolio of over 280 pharmaceutical innovators.It boasts partnerships with 18 of the top 25 global pharmaceutical giants, ranked by revenue in 2023.
Global Reach:Sai Life Sciences operates across major markets, including the United States, United Kingdom, Europe, and Japan.Core Services:
- Chemistry, Manufacturing, and Control (CMC) or Contract Development and Manufacturing (CDMO): Comprehensive solutions for drug development and manufacturing.Contract Research Organization (CRO): Offers advanced discovery capabilities in areas like biology, chemistry, drug metabolism, and pharmacokinetics. Promoter Shareholding
Promoters:The company’s ownership includes Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, and private equity partners like Sunflower, Lily, Marigold, and Tulip Partners.
- Pre-Issue Shareholding: 40.48%Post-Issue Shareholding: 35.1% Objects of the IPO
The funds raised through the IPO will be utilized for the following purposes:
Debt Reduction: To significantly decrease the company’s financial liabilities.Corporate Expansion: To support business development and improve operational efficiency.
Summary of Financial Information:
| Period Ended | 30-Sep-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Revenue | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Reserves and Surplus | 1,025.44 | 953.99 | 867.43 | 859.17 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
Comparison with Listed Peers:
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio |
|---|---|---|---|---|---|---|
| Sai Life Sciences Limited | 4.57 | 4.53 | 53.83 | 8.5 | ||
| DIVI'S LABORATORIES Limited | 60.27 | 60.27 | 511.21 | 103.04 | 11.79 | 6.72 |
| Suven Pharmaceuticals Limited | 11.8 | 11.8 | 94.04 | 109.37 | 14.64 | 7.2 |
| Syngene International Ltd | 12.71 | 12.69 | 105.91 | 73.59 | 11.98 | 6.69 |
Key IPO Details:
- IPO Dates: 11 to 13 December, 2024
- Price Band: Rs. 522 to Rs. 549 per share
- Lot Size: 27 shares
- Issue Size: Rs. 3042.62 Crores (Fresh Issue: Rs. 950 Cr.)
- Retail Quota: 35%
- Listing Date: 18th Dec, 2024
- GMP: 5%+ (for informational purposes only)
Note: For additional information & risk factors please refer to the Red Herring Prospectus
Join our WhatsApp Group for Trading/Investment ideas & Market Updates 👇
Disclaimer: We are not SEBI registered. All the views are personal and only for educational purposes. Do your due diligence before making any trading or investing decisions. The data provided in this blog post is for illustrative purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.
